Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Renews Agreement with Agilent for Microfluidic Chips

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced it has renewed its microfluidic chip supply agreement with Agilent Technologies.

Under a new seven-year agreement, Caliper will remain the exclusive supplier of microfluidic chips to Agilent for use on its Bioanalyzer 2100 platforms. Since its launch in 1999, more than 7,000 Bioanalyzer 2100 instruments have been sold, and Caliper has supplied about 5 million chips for use on the platform, Caliper said in a statement.

Agilent is Caliper's largest original equipment manufacturer customer and accounted for about 15 percent of Caliper's total microfluidic sales in 2009, Kevin Hrusovsky, president and CEO of Caliper said. In 2010 the business is expected to increase between 10 and 15 percent, "and the renewal of this relationship with its improved economics is a vital element of our strategy for sustainable double-digit growth in our microfluidics franchise over the long term," he said.

"We believe that our microfluidics technologies will continue growing as a critical tool for sample analysis as well as for sample preparation, particularly as sequencing and gene expression workflows become fundamental to the realization of personalized medicine," he added.

Financial terms of the agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.